The role of CD95 and CD95 ligand in cancer
2015 · Cell Death and Differentiation · 336 citations
https://doi.org/10.1038/cdd.2015.3
P
Paolo Ceppi
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
114
Papers
4.6K
Citations
34
h-index
49
i10-index
Paolo Ceppi is an academic researcher from University of Southern Denmark. The author has contributed to research in topics: Lung Cancer Treatments and Mutations & RNA modifications and cancer & Cancer, Hypoxia, and Metabolism. The author has an h-index of 34, co-authored 97 publications.
ORCID: 0000-0002-3632-8476Papers by this author
worksTargeting EMT in Cancer with Repurposed Metabolic Inhibitors
2020 · Trends in cancer · 243 citations
https://doi.org/10.1016/j.trecan.2020.06.005
CD95/Fas Increases Stemness in Cancer Cells by Inducing a STAT1-Dependent Type I Interferon Response
2017 · Cell Reports · 109 citations
https://doi.org/10.1016/j.celrep.2017.02.037
Death Induced by CD95 or CD95 Ligand Elimination
2014 · Cell Reports · 83 citations
https://doi.org/10.1016/j.celrep.2014.02.035
Aurora Kinase A expression is associated with lung cancer histological-subtypes and with tumor de-differentiation
2011 · Journal of Translational Medicine · 60 citations
https://doi.org/10.1186/1479-5876-9-100
Human ASH1 expression in prostate cancer with neuroendocrine differentiation
2008 · Modern Pathology · 57 citations
https://doi.org/10.1038/modpathol.2008.39
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat